Design Therapeutics, INC

Design Therapeutics announced its second quarter 2026 financial results, highlighting progress in its RESTORE-FA trial for Friedreich's ataxia and initiation of a Phase 1 trial for DT-818 in myotonic dystrophy type 1, while also noting a delay in its FECD program.

Design Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of a director and the ratification of its independent auditor.

Design Therapeutics announced positive biomarker and clinical data from its Phase 1/2 RESTORE-FA trial for DT-216P2 in Friedreich's Ataxia patients.

Design Therapeutics, Inc. announced the appointment of Dr. David Shapiro to its Board of Directors and Nominating and Corporate Governance Committee, effective March 31, 2026.

Deepa Prasad has resigned from Design Therapeutics' Board of Directors, effective February 1, 2026, due to conflict-avoidance policies related to a new role at a major bank.

Design Therapeutics announced the nomination of DT-818 for Myotonic Dystrophy Type-1, obtained ex-US regulatory clearance, and reported its third quarter 2025 financial results.

Design Therapeutics, Inc. (DSGN) filed its Form 10-Q for the quarter ended June 30, 2026, detailing advancements in its GeneTAC platform, particularly for Friedreich's Ataxia, while reporting continued net losses.

Design Therapeutics, Inc. reported its first quarter 2026 financial results, highlighting progress in its GeneTAC molecule development for rare diseases and a net loss of $17.6 million.

Design Therapeutics, a clinical-stage biopharmaceutical company, reported increased net losses for Q3 2025 while progressing its GeneTAC molecule pipeline, despite an FDA clinical hold on its lead FA program in the U.S.

Design Therapeutics reported increased net losses in Q2 2025, driven by higher R&D expenses, and disclosed an FDA clinical hold on its lead FA program, DT-216P2, for the U.S. starting dose.

Design Therapeutics reports a net loss for Q1 2025 and provides updates on its GeneTAC molecule development programs targeting inherited nucleotide repeat expansion diseases.

Design Therapeutics reported its third quarter 2024 financial results and provided updates on its clinical development programs, including a revised timeline for its Friedreich ataxia program.

Design Therapeutics continues to advance its GeneTAC platform, focusing on treatments for inherited nucleotide repeat expansion diseases, with key clinical trials anticipated in 2025 and 2026.

Design Therapeutics' 10-K filing details the rights and preferences of common stockholders, anti-takeover provisions, and regulatory compliance, providing a comprehensive overview of the company's governance and operational structure.

Director Simeon George was granted 30,000 stock options in Design Therapeutics, Inc. with an exercise price of $10.55.

John P. Schmid, a Director at Design Therapeutics, Inc., acquired 30,000 stock options with an exercise price of $10.55.

Rodney W. Lappé, a Director at Design Therapeutics, Inc., acquired 30,000 stock options on June 9, 2026, as part of a pre-planned transaction.

Design Therapeutics Director Justin D. Gover acquired 30,000 stock options with an exercise price of $10.55 on June 9, 2026.

David Shapiro, a Director at Design Therapeutics, Inc., acquired 30,000 stock options.

Heather A. Berger, a Director at Design Therapeutics, Inc., acquired 30,000 stock options with an exercise price of $10.55.

Design Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, to elect a Class II director and ratify the appointment of Ernst & Young LLP as its independent auditor.

Design Therapeutics has released its proxy statement for the 2025 Annual Meeting of Stockholders, detailing proposals for director elections and auditor ratification.

Design Therapeutics will hold its annual stockholders meeting on June 10, 2025, to elect directors and ratify the selection of Ernst & Young LLP as its independent accounting firm.

Design Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 10, 2025, to elect directors and ratify the selection of its independent accounting firm.

Design Therapeutics, Inc. will hold its annual stockholders meeting on June 13, 2024, to elect a Class III director and ratify the selection of Ernst & Young LLP as its independent auditor.

Design Therapeutics announces its 2024 Annual Meeting of Stockholders to be held on June 13, 2024, to elect a director and ratify the selection of Ernst & Young LLP as the independent accounting firm.

SR One Capital reports a decrease in its beneficial ownership percentage of Design Therapeutics, Inc. common stock due to an increase in the total outstanding shares.

Logos Global Management LP and affiliated entities, including Arsani William, have reduced their beneficial ownership in Design Therapeutics, Inc. to 4.4% following Dr. William's resignation from the board.

Logos Global Management LP and affiliated entities updated their beneficial ownership in Design Therapeutics, Inc. to 5.7% following a share sale and the resignation of Dr. Arsani William from the board.

Point72 Asset Management and Steven A. Cohen have reported a 5.1% beneficial ownership stake in Design Therapeutics, Inc.

Point72 Asset Management and Steven A. Cohen have reported a 4.4% beneficial ownership stake in Design Therapeutics, Inc. as of March 31, 2026.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 5.2% beneficial ownership stake in Design Therapeutics, Inc.

An amended Schedule 13G filing reveals that Star Irrevocable Trust #1 holds a 6.9% beneficial ownership stake in Design Therapeutics, Inc. as of December 31, 2024.

Light Irrevocable Trust #1, along with Jason Howerton, has filed an amended Schedule 13G disclosing a 6.9% beneficial ownership stake in Design Therapeutics, Inc. as of December 31, 2024.